Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors

MT Newswires Live

Mar 04

Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.

The trial covers patients with unresectable, advanced or metastatic solid tumors.

In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.

Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2616390515"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616390515\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616390515?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616390515","market":"sh","top_or_hot":-1,"title":"Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.</p><p>The trial covers patients with unresectable, advanced or metastatic solid tumors.</p><p>In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.</p><p>Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-04 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.</p><p>The trial covers patients with unresectable, advanced or metastatic solid tumors.</p><p>In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.</p><p>Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616390515","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616390515","pubTimestamp":1772621438,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed  said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.The trial covers patients with unresectable, advanced or metastatic solid tumors.In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4531":"中概回港概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","HCM":"和黄医药"},"translate_title":"和黄医药启动HMPL-A580在实体瘤患者中的全球试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1},"content_text":"Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.The trial covers patients with unresectable, advanced or metastatic solid tumors.In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}